Literature DB >> 17962340

Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

H S Freitas1, G F Anhê, K F S Melo, M M Okamoto, M Oliveira-Souza, S Bordin, U F Machado.   

Abstract

Mutations in Na(+)-glucose transporters (SGLT)-2 and hepatocyte nuclear factor (HNF)-1alpha genes have been related to renal glycosuria and maturity-onset diabetes of the young 3, respectively. However, the expression of these genes have not been investigated in type 1 and type 2 diabetes. Here in kidney of diabetic rats, we tested the hypotheses that SGLT2 mRNA expression is altered; HNF-1alpha is involved in this regulation; and glycemic homeostasis is a related mechanism. The in vivo binding of HNF-1alpha into the SGLT2 promoter region in renal cortex was confirmed by chromatin immunoprecipitation assay. SGLT2 and HNF-1alpha mRNA expression (by Northern and RT-PCR analysis) and HNF-1 binding activity of nuclear proteins (by EMSA) were investigated in diabetic rats and treated or not with insulin or phlorizin (an inhibitor of SGLT2). Results showed that diabetes increases SGLT2 and HNF-1alpha mRNA expression (~50%) and binding of nuclear proteins to a HNF-1 consensus motif (~100%). Six days of insulin or phlorizin treatment restores these parameters to nondiabetic-rat levels. Moreover, both treatments similarly reduced glycemia, despite the differences in plasma insulin and urinary glucose concentrations, highlighting the plasma glucose levels as involved in the observed modulations. This study shows that SGLT2 mRNA expression and HNF-1alpha expression and activity correlate positively in kidney of diabetic rats. It also shows that diabetes-induced changes are reversed by lowering glycemia, independently of insulinemia. Our demonstration that HNF-1alpha binds DNA that encodes SGLT2 supports the hypothesis that HNF-1alpha, as a modulator of SGLT2 expression, may be involved in diabetic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962340     DOI: 10.1210/en.2007-1088

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  61 in total

Review 1.  Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Authors:  Volker Vallon; Kumar Sharma
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  A fluorescence method for measurement of glucose transport in kidney cells.

Authors:  Amy B Blodgett; Rajendra K Kothinti; Ivan Kamyshko; David H Petering; Suresh Kumar; Niloofar M Tabatabai
Journal:  Diabetes Technol Ther       Date:  2011-04-21       Impact factor: 6.118

Review 3.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

Review 4.  Renal glucose transporters: novel targets for hyperglycemia management.

Authors:  Amanda Mather; Carol Pollock
Journal:  Nat Rev Nephrol       Date:  2010-03-30       Impact factor: 28.314

Review 5.  Fructose and uric acid in diabetic nephropathy.

Authors:  Petter Bjornstad; Miguel A Lanaspa; Takuji Ishimoto; Tomoki Kosugi; Shinji Kume; Diana Jalal; David M Maahs; Janet K Snell-Bergeon; Richard J Johnson; Takahiko Nakagawa
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

Review 6.  SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys.

Authors:  Frederik H Verbrugge; Pieter Martens; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2017-08

7.  Na+-glucose cotransporter SGLT1 protein in salivary glands: potential involvement in the diabetes-induced decrease in salivary flow.

Authors:  R Sabino-Silva; H S Freitas; M L Lamers; M M Okamoto; M F Santos; U F Machado
Journal:  J Membr Biol       Date:  2009-02-24       Impact factor: 1.843

Review 8.  Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.

Authors:  Jagriti Bhatia; Nanda Gamad; Saurabh Bharti; Dharamvir Singh Arya
Journal:  World J Diabetes       Date:  2014-06-15

Review 9.  1,5-Anhydroglucitol in diabetes mellitus.

Authors:  Won Jun Kim; Cheol-Young Park
Journal:  Endocrine       Date:  2012-07-31       Impact factor: 3.633

Review 10.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.